staphylococcus

Pathogenesis and Immunity

1. Defenses against Innate Immunity

   • Capsule: Provides protection from phagocytosis.

   • Slime Layer: Interferes further with phagocytic processes.

   • Protein A: Binds to the $Fc$ portion of immunoglobulin $G$ ($IgG$), allowing the bacteria to evade antibody-mediated immune clearance.

2. Adhesion Proteins

   • Teichoic acid and various surface proteins facilitate adherence to host tissues.

   • MSCRAMM (microbial surface components recognizing adhesive matrix molecules) and coagulase are key surface proteins for host attachment.

3. Staphylococcal Toxins

   • Cytotoxins:

   1. Alpha toxin ($\alpha$): Causes pore formation in cell membranes; disrupts smooth muscle in blood vessels; toxic to RBCs, WBCs, hepatocytes, and platelets.

   2. Beta toxin ($\beta$ - sphingomyelinase C): Hydrolyzes membrane phospholipids; toxic to fibroblasts, RBCs, and macrophages.

   3. Delta toxin ($\delta$): Acts as a detergent to disrupt cellular membranes.

   4. Gamma toxin ($\gamma$): Forms pores to lyse neutrophils and macrophages; frequently associated with MRSA.

   • Exfoliative Toxins:

   • Serine proteases responsible for Staphylococcal Scalded Skin Syndrome (SSSS).

   • Disrupt cell adhesion in the epidermis, leading to dermal separation.

   • Enterotoxins:

   • Enterotoxin A: Most common toxin linked to food poisoning.

   • Enterotoxin B: Linked to staphylococcal pseudomembranous enterocolitis.

   • Enterotoxins C and D: Found in contaminated dairy products.

   • These act as superantigens, triggering massive cytokine release via $T$ cell activation.

   • Toxic Shock Syndrome Toxin-1 (TSST-1):

   • A heat-stable exotoxin linked to both menstruation-related and wound-associated Toxic Shock Syndrome (TSS), leading to multi-organ failure.

4. Staphylococcal Enzymes

   • Coagulase: Converts fibrinogen to fibrin to facilitate clumping.

   • Hyaluronidase: Hydrolyzes connective tissue components.

   • Fibrinolysin: Dissolves fibrin clots.

   • Lipases: Hydrolyze lipids for survival in fatty environments (e.g., skin).

Epidemiology

• Prevalence: Staphylococci are ubiquitous; approximately $30\%$ of healthy adults are carriers.

• Carriage sites:

  • Coagulase-negative: Skin and urogenital tracts.

  • Coagulase-positive ($S. aureus$): Nasopharynx.

• High-Risk Populations: Hospitalized individuals, medical personnel, needle users, and patients with eczema.

• Transmission:

  • Direct person-to-person contact

  • Fomites (contaminated surfaces)

  • Contaminated food products

• Stability: Organisms can survive for long periods on dry surfaces.

Symptoms and Clinical Diseases

1. Staphylococcal Scalded Skin Syndrome (SSSS):

   • Starts with localized erythema around the mouth.

   • Progresses to widespread bullous exfoliative dermatitis (blisters).

   • Primarily affects infants; mortality rate is < 5\%.

2. Staphylococcal Food Poisoning:

   • Rapid symptom onset ($2-4$ hours) due to pre-formed toxins.

   • Symptoms: Severe vomiting, diarrhea, abdominal pain, and dehydration.

   • Notably, fever is generally absent.

3. Toxic Shock Syndrome (TSS):

   • Manifests as fever, hypotension, and a characteristic erythematous rash.

   • Potential for purpura fulminans; associated with a high recurrence risk ($65\%$).

4. Pyogenic Cutaneous Infections:

   • Impetigo: Small red macules progressing to pus-filled vesicles.

   • Characterized by localized edema, pain, and erythema.

Treatment, Prevention, and Control

1. Challenges: Control is difficult because the organism is ubiquitous.

2. MRSA (Methicillin-resistant S. aureus):

   • Rising trends in resistance since the late $1990\text{s}$.

   • Approximately $5\%$ of the population are MRSA carriers.

3. Impact: Annual bloodstream cases are estimated at $119,000$, leading to approximately $20,000$ deaths. Access points often include minor wounds or surgical sites.